Description: SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
Home Page: www.skbp.com
221, Pangyoyeok-ro
Seongnam-si,
13494
South Korea
Phone:
82 31 8093 0114
Officers
| Name | Title |
|---|---|
| Mr. Dong Hoon Lee | CEO & Chairman |
| Mr. Jeong Woo Cho Ph.D. | Pres, CEO & Director |
| Mr. Jiyoung Jung | VP & CFO |
| Mr. Kiho Lee Ph.D. | VP & CTO |
| Mr. Jooyup Chae | VP & Gen. Counsel |
| Mr. Wanho Nam | VP and Head of Corp. Culture & HR |
| Mr. Changho Yu C.F.A. | VP & Chief Strategy Officer |
| Ms. Jungshin Park Ph.D. | VP & Head of Drug Devel. Bus. Unit |
| Mr. Sungwan Hwang | VP and Head of R&D Innovation |
| Hyung-Rae Cho | Fin. Exec. |
Exchange: KO
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.894 |
| Price-to-Sales TTM: | 13.9363 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |